TrialBMC cancer2022

A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study.

Martina Eriksen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.